Pilocarpine and carbacholine in treatment of radiation-induced xerostomia.
Twenty-four patients with radiation-related xerostomia were treated with oral pilocarpine solution 6 mg t.i.d., and after a 4-week drug-free period 16 of these patients were treated with carbacholine 2 mg tablets t.i.d. Basal and stimulated whole saliva flow rates were measured before commencing the drug treatment, and after 1 and 12 weeks on treatment. On a subjective linear scale both pilocarpine (p = 0.01) and carbacholine (p = 0.02) improved mouth moistness. Only 2 of the 8 patients with no basal or stimulated saliva flow reported some subjective benefit from the drug treatment, whereas all 8 patients with less severe xerostomia improved (p = 0.007). However, the salivary flow rates measured 12 h after the last drug dose did not improve with either drug. Both drugs were generally well tolerated. It is concluded that both drugs may be useful in the treatment of radiation-induced xerostomia among patients with residual salivary function.
Joensuu
H
H
Department of Oncology and Radiotherapy, Turku University Central Hospital, Finland.
Boström
P
P
Makkonen
T
T
D000328:Adult; D000368:Aged; D002217:Carbachol / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010862:Pilocarpine / Q000008:administration & dosage* / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects*; D012472:Salivation / Q000187:drug effects / Q000528:radiation effects; D014987:Xerostomia / Q000188:drug therapy* / Q000209:etiology*
D010862:Pilocarpine; D002217:Carbachol